Comparison · NCT04068103-deaths
Arm I (Blood Stored and Tested for ctDNA Later) vs Arm II (Blood Tested for ctDNA at Baseline): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Blood Stored and Tested for ctDNA Later) vs Arm II (Blood Tested for ctDNA at Baseline): deaths from any cause. Trial comparisons, record NCT04068103-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04068103-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0252 | 0.0128 | 0.0488 | wilson | |
| Risk in group 2 | 0.0189 | 0.0087 | 0.0407 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00623 | -0.0188 | 0.032 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.467 | 3.79 | log | |
| Odds ratio, group 1 over group 2 | 1.34 | 0.459 | 3.9 | log | |
| Number needed to harm, for one more death from any cause on Arm I (Blood Stored and Tested for ctDNA Later) than on Arm II (Blood Tested for ctDNA at Baseline) | 161 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Blood Stored and Tested for ctDNA Later) | Arm I (blood stored and tested for ctDNA later). AEs were NOT assessed in this arm. | 8 | 318 | EG000 |
| Group 2 | Arm II (Blood Tested for ctDNA at Baseline) | Arm II (blood tested for ctDNA at baseline). Positive ctDNA and Treated assessed in this arm. | 6 | 317 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- AEs assessed during and up to 30 days after therapy, about 28 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- NCT number
- NCT04068103
- Phases
- PHASE2, PHASE3
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
- Interventions
- Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
- Lead sponsor
- NRG Oncology
- Results first posted
- 2025-04-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04068103?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04068103-deaths